BHP, Rio Tinto shares rise as peer Vale posts smaller-than-feared Q2 profit drop
James Ziegler, the Executive Vice President and Chief Commercial Officer of Geron Corp (NASDAQ:GERN), recently made a significant acquisition of company shares. According to a recent SEC filing, Ziegler purchased 100,000 shares of Geron Corp at a price of $1.60 per share, amounting to a total transaction value of $160,000. This transaction took place on February 27, 2025, and was executed as an open market purchase. Following this transaction, Ziegler’s direct ownership in Geron Corp now stands at 100,000 shares. The purchase comes as the stock has declined over 60% in the past six months, though InvestingPro analysis suggests the stock is currently trading below its Fair Value.
Geron Corp, based in Foster City, California, is a company involved in the pharmaceutical preparations industry. The purchase reflects Ziegler’s confidence in the company’s prospects as it continues to operate within the life sciences sector. The company maintains a strong liquidity position with a current ratio of 5.56 and more cash than debt on its balance sheet. InvestingPro subscribers can access 12 additional key insights about Geron’s financial health and market position, along with comprehensive analysis in the Pro Research Report.
In other recent news, Geron Corporation reported fourth-quarter revenue of $47.5 million, which was below the anticipated $61.93 million, leading to a significant market reaction. The company also reported earnings per share of ($0.04), missing the consensus estimate of ($0.03). Despite these figures, Geron maintains a strong cash position and expressed optimism about its drug Rytelo, particularly in treating lower-risk myelodysplastic syndromes. Analysts from Stifel and Scotiabank (TSX:BNS) have adjusted their price targets for Geron to $4, citing concerns about flattening sales and the slower uptake of Rytelo. TD Cowen also reduced its price target to $5 while maintaining a Buy rating, emphasizing the need for increased adoption in earlier therapy lines. H.C. Wainwright downgraded Geron to a Neutral rating, reflecting reduced confidence in near-term revenue growth and revised sales forecasts. The company is focusing on strategic physician engagement and education to address these challenges. Geron plans to explore further applications for Rytelo through investigator-sponsored trials in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.